Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Baxter
AstraZeneca
Harvard Business School
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

UPTRAVI Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Uptravi patents expire, and when can generic versions of Uptravi launch?

Uptravi is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred patent family members in thirty-three countries.

The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selexipag profile page.

Drug patent expirations by year for UPTRAVI
Drug Prices for UPTRAVI

See drug prices for UPTRAVI

Generic Entry Opportunity Date for UPTRAVI
Generic Entry Date for UPTRAVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for UPTRAVI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ActelionPhase 3
ActelionPhase 4

See all UPTRAVI clinical trials

Recent Litigation for UPTRAVI

Identify potential future generic entrants

District Court Litigation
Case NameDate
NIPPON SHINYAKU CO., LTD. v. KAPPOS2010-07-06

See all UPTRAVI litigation

Pharmacology for UPTRAVI
Synonyms for UPTRAVI
144383-EP2289518A1
144383-EP2292231A1
2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide
2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide
2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide
2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide
2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide
2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
3938AH
475086-01-2
5EXC0E384L
AC-30209
ACT 293987
ACT-293987
AK298890
AKOS024457572
B7378
BCP09146
CHEBI:90844
CHEMBL238804
CS-3774
CTK8F0123
D09994
DB11362
GTPL7552
HY-14870
KB-79567
KS-00000L89
MolPort-009-019-323
NCGC00370833-01
NS 304
NS 304; ACT 293987; Uptravi
NS-304
NS-304(Selexipag)
QXWZQTURMXZVHJ-UHFFFAOYSA-N
RT-014761
SB17055
SCHEMBL674122
Selexipag
Selexipag (JAN/USAN/INN)
Selexipag [USAN:INN]
Selexipag(NS-304)
UNII-5EXC0E384L
Uptravi (TN)
ZINC3990451

US Patents and Regulatory Information for UPTRAVI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 RX Yes No   See Pricing   See Pricing   See Pricing
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No   See Pricing   See Pricing   See Pricing
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes   See Pricing   See Pricing Y Y   See Pricing
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No   See Pricing   See Pricing Y Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for UPTRAVI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1400518 CA 2016 00048 Denmark   See Pricing PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
1400518 532 Finland   See Pricing
2447254 2018015 Norway   See Pricing PRODUCT NAME: 2-4-(N-(5,6-DIFENYLPYRAZIN-2- YL)-N- ISOPROPYLAMINO)BUTYLOKSY-N-; REG. NO/DATE: EU/1/15/1083 20160530
1400518 16C0042 France   See Pricing PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Medtronic
Colorcon
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.